Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (121-130 of 339) with videos related to

Pageof 34
Sort By:
Scientific Reports|July 4, 2023
Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experiencePaul Jäger, Christina Rautenberg, Jennifer Kaivers, et al.
Cancers|July 29, 2023
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk ScoreTobias Silzle, Sabine Blum, Annika Kasprzak, et al.
European Journal of Haematology|November 29, 2016
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCTChristina Rautenberg, Kathrin Nachtkamp, Ariane Dienst, et al.
Haematologica|July 4, 2007
Chronic myelomonocytic leukemia in the light of the WHO proposalsUlrich Germing, Corinna Strupp, Sabine Knipp, et al.
Haematologica|February 16, 2015
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromesMaryam Hejazi, Angela R Manser, Julia Fröbel, et al.
Annals of Hematology|March 30, 2019
Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignanciesEsther Schuler, Sarah Boughoufala, Christina Rautenberg, et al.
BMC Cancer|May 21, 2022
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studiesUwe Platzbecker, Joerg Chromik, Jan Krönke, et al.
Cancers|August 19, 2020
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell TransplantationChristina Rautenberg, Anika Bergmann, Ulrich Germing, et al.
Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.
Blood Cancer Journal|November 13, 2019
EASIX for prediction of survival in lower-risk myelodysplastic syndromesAlmuth Merz, Ulrich Germing, Guido Kobbe, et al.
Pageof 34

Showing results (121-130 of 339) with videos related to

Sort By:
Pageof 34
Scientific Reports|July 4, 2023
Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experiencePaul Jäger, Christina Rautenberg, Jennifer Kaivers, et al.
Cancers|July 29, 2023
The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk ScoreTobias Silzle, Sabine Blum, Annika Kasprzak, et al.
European Journal of Haematology|November 29, 2016
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCTChristina Rautenberg, Kathrin Nachtkamp, Ariane Dienst, et al.
Haematologica|July 4, 2007
Chronic myelomonocytic leukemia in the light of the WHO proposalsUlrich Germing, Corinna Strupp, Sabine Knipp, et al.
Haematologica|February 16, 2015
Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromesMaryam Hejazi, Angela R Manser, Julia Fröbel, et al.
Annals of Hematology|March 30, 2019
Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignanciesEsther Schuler, Sarah Boughoufala, Christina Rautenberg, et al.
BMC Cancer|May 21, 2022
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studiesUwe Platzbecker, Joerg Chromik, Jan Krönke, et al.
Cancers|August 19, 2020
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell TransplantationChristina Rautenberg, Anika Bergmann, Ulrich Germing, et al.
Blood|February 1, 2007
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndromePierre Fenaux, Azra Raza, Ghulam J Mufti, et al.
Blood Cancer Journal|November 13, 2019
EASIX for prediction of survival in lower-risk myelodysplastic syndromesAlmuth Merz, Ulrich Germing, Guido Kobbe, et al.
Pageof 34